Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans

Neuropsychopharmacology

Volumn 40, Issue 9, 2015, Pages 2124-2134

  Cortes Briones, Jose ^a,b   Skosnik, Patrick D ^a,b,c   Mathalon, Daniel ^b,d,e   Cahill, John ^a,b,c   Pittman, Brian ^b,c   Williams, Ashley ^a,c   Sewell, R Andrew ^a,b,c   Ranganathan, Mohini ^a,b,c   Roach, Brian ^d,e   Ford, Judith ^b,d,e   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Abraham Ribicoff Research Facilities   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; PLACEBO; DELTA(9)-TETRAHYDROCANNABINOLIC ACID; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; AUDITORY RESPONSE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; OSCILLATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ADOLESCENT; ANALOGS AND DERIVATIVES; AUDITORY STIMULATION; BLOOD; DRUG EFFECTS; FOURIER ANALYSIS; GAMMA RHYTHM; PSYCHOLOGICAL RATING SCALE; PSYCHOPHYSICS; YOUNG ADULT;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRONABINOL; ELECTROENCEPHALOGRAPHY; FEMALE; FOURIER ANALYSIS; GAMMA RHYTHM; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOACOUSTICS; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84937162867     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.53     Document Type: Article

References (81)

1. Ali AB, Todorova M (2010). Asynchronous release of GABA via tonic cannabinoid receptor activation at identified interneuron synapses in rat CA1. Eur J Neurosci 31: 1196-1207.
2. Bacci A, Huguenard JR, Prince DA (2004). Long-lasting self-inhibition of neocortical interneurons mediated by endocannabi-noids. Nature 431: 312-316.
3. Bartos M, Elgueta C (2012). Functional characteristics of parvalbu-min-and cholecystokinin-expressing basket cells. J Physiol 590: 669-681.
4. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N et al (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845-6856.
5. Buzsaki G, Wang XJ (2012). Mechanisms of gamma oscillations. Annu Rev Neurosci 35: 203-225.
6. Cannon J, McCarthy MM, Lee S, Lee J, Borgers C, Whittington MA et al (2014). Neurosystems: brain rhythms and cognitive processing. Eur J Neurosci 39: 705-719.
7. Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J et al (2011). The safety of studies with intravenous Delta (9)-tetrahydrocannabinol in humans, with case histories. Psycho-pharmacology (Berl) 219: 885-896.
8. Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyi P (1995). Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature 378: 75-78.
9. Csicsvari J, Jamieson B, Wise KD, Buzsáki G (2003). Mechanisms of gamma oscillations in the hippocampus of the behaving rat. Neuron 37: 311-322.
10. Curley AA, Lewis DA (2012). Cortical basket cell dysfunction in schizophrenia. J Physiol 590: 715-724.
11. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B et al (2008a). Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 198: 587-603.
12. D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N et al (2012). Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ9-THC in humans. Neuropsychopharmacology 37: 1632-1646.
13. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
14. D'Souza DC, Pittman B, Perry E, Simen A (2009). Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl) 202: 569-578.
15. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T et al (2008b). Blunted psychotomimetic and amnestic effects of Delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505-2516.
16. Davies L, Gather U (1993). The identification of multiple outliers. J Am Stat Assoc 88: 782-792.
17. De Clercq W, Vergult A, Vanrumste B, Van Paesschen W, Van Huffel S (2006). Canonical correlation analysis applied to remove muscle artifacts from the electroencephalogram. IEEE Trans Biomed Eng 53: 2583-2587.
18. Delorme A, Makeig S (2004). EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 134: 9-21.
19. Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191.
20. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA (2010). Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 169: 1651-1661.
21. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-Patient Edition. American Psychiatric Association: Washington, DC.
22. Foldy C, Aradi I, Howard A, Soltesz I (2004). Diversity beyond variance: modulation of firing rates and network coherence by GABAergic subpopulations. Eur J Neurosci 19: 119-130.
23. Foldy C, Neu A, Jones MV, Soltesz I (2006). Presynaptic, activity-dependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci 26: 1465-1469.
24. Freund TF (2003). Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends Neurosci 26: 489-495.
25. Gandal MJ, Edgar JC, Klook K, Siegel SJ (2012). Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology 62: 1504-1518.
26. Gómez-Herrero G, De Clercq W, Anwar H, Kara O, Egiazarian K, Van Huffel S et al (eds) (2006). Automatic removal of ocular artifacts in the EEG without an EOG reference channel. Signal Processing Symposium, 2006. NORSIG 2006. Proceedings of the 7th Nordic. IEEE.
27. Goncharova I, McFarland DJ, Vaughan TM, Wolpaw JR (2003). EMG contamination of EEG: spectral and topographical characteristics. Clin Neurophysiol 114: 1580-1593.
28. Gonzalez-Burgos G, Lewis DA (2008). GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34: 944-961.
29. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81: 300-318.
30. Haig AR, Gordon E, De Pascalis V, Meares RA, Bahramali H, Harris A (2000). Gamma activity in schizophrenia: evidence of impaired network binding? Clin Neurophysiol 111: 1461-1468.
31. Hajos M, Hoffmann WE, Kocsis B (2008). Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63: 1075-1083.
32. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249.
33. Hampel FR (1974). The influence curve and its role in robust estimation. J Am Stat Assoc 69: 383-393.
34. Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P et al (2007). Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophy-siol 97: 2580-2589.
35. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C et al (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17: 642-649.
36. Holderith N, Nemeth B, Papp OI, Veres JM, Nagy GA, Hajos N (2011). Cannabinoids attenuate hippocampal gamma oscillations by suppressing excitatory synaptic input onto CA3 pyramidal neurons and fast spiking basket cells. J Physiol 589: 4921-4934.
37. Johnson LA, Johnson RL, Alfonzo C (2011). Spice: a legal marijuana equivalent. Mil Med 176: 718-720.
38. Johnston LD, O'Malley PM, Bachman HG, Schulenberg JE (2012). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2011. Institute for Social Research, The University of Michigan: Ann Arbor.
39. Jones RT, Benowitz NL, Herning RI (1981). Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21: 143S-152S.
40. Karson MA, Tang AH, Milner TA, Alger BE (2009). Synaptic cross talk between perisomatic-targeting interneuron classes expressing cholecystokinin and parvalbumin in hippocampus. J Neurosci 29: 4140-4154.
41. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000). GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797-804.
42. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D et al (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628-5637.
43. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M et al (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991-3001.
44. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 59-67.
45. Keimpema E, Straiker A, Mackie K, Harkany T, Hjerling-Leffler J (2012). Sticking out of the crowd: the molecular identity and development of cholecystokinin-containing basket cells. J Physiol 590: 703-714.
46. Kleber HD, DuPont RL (2012). Physicians and medical marijuana. Am J Psychiatry 169: 564-568.
47. Krishnan GP, Hetrick WP, Brenner CA, Shekhar A, Steffen AN, O'Donnell BF (2009). Steady state and induced auditory gamma deficits in schizophrenia. NeuroImage 47: 1711-1719.
48. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG et al (1999). Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 56: 1001-1005.
49. Liang K-Y, Zeger SL (1986). Longitudinal data analysis using generalized linear models. Biometrika 73: 13-22.
50. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR et al (2006). Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 60: 1231-1240.
51. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS et al (2010). Potency trends of Delta9-THC and other cannabi-noids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55: 1209-1217.
52. Morgan NH, Stanford IM, Woodhall GL (2008). Modulation of network oscillatory activity and GABAergic synaptic transmission by CB1 cannabinoid receptors in the rat medial entorhinal cortex. Neural Plast 2008: 808564.
53. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF et al (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39: 1607-1616.
54. ONDCP (2008). Marijuana: The Greatest Cause of Illegal Drug Abuse. The Marijuana Factbook. Executive Office of the President Washington: DC, 20503.
55. Partha M, Hemant B (2007). Observed Brain Dynamics. Oxford University Press: New York.
56. Procon.org (2014). Medical marijuana http://medicalmarijuana. procon.org/Vol. 2014.
57. ∞ adaptive filters for eye blink artifact minimization from electroencephalogram. Signal Processing Lett IEEE 12: 816-819.
58. Radhakrishnan R, Wilkinson ST, D'Souza DC (2014). Gone to pot-a review of the association between cannabis and psychosis. Front Psychiatry 5.
59. Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J et al (2009). The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl) 203: 737-744.
60. Roach B, Ford J, Hoffman R, Mathalon D (2012). Converging evidence for gamma synchrony deficits in schizophrenia. Suppl Clin Neurophysiol 62: 163-180.
61. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9: 1526-1533.
62. Sales-Carbonell C, Rueda-Orozco PE, Soria-Gomez E, Buzsaki G, Marsicano G, Robbe D (2013). Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabi-noids on cortical network synchrony. Proc Natl Acad Sci USA 110: 719-724.
63. SAMHSA (2011). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration: Rockville, MD.
64. SAMHSA (2012). Drug Abuse Warning Network, 2010: National Estimates of Drug-Related Emergency Department Visits. Center for Behavioral Health Statistics and Quality (formerly the Office of Applied Studies), Substance Abuse and Mental Health Services Administration (SAMHSA): Rockville, MD.
65. Skosnik P, Krishnan G, Aydt E, Kuhlenshmidt H, O'Donnell B (2006). Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 163: 1798-1805.
66. Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP et al (2012). The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychophar-macology 37: 2184-2193.
67. Sohal VS (2012). Insights into cortical oscillations arising from optogenetic studies. Biol Psychiatry 71: 1039-1045.
68. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459: 698-702.
69. Spencer KM, Salisbury DF, Shenton ME, McCarley RW (2008a). Gamma-band auditory steady-state responses are impaired in first episode psychosis. Biol Psychiatry 64: 369-375.
70. Spencer KM, Salisbury DF, Shenton ME, McCarley RW (2008b). γ-Band auditory steady-state responses are impaired in first episode psychosis. Biol Psychiatry 64: 369-375.
71. Tallon-Baudry C, Bertrand O, Delpuech C, Pernier J (1996). Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human. J Neurosci 16: 4240-4249.
72. Tukker JJ, Fuentealba P, Hartwich K, Somogyi P, Klausberger T (2007). Cell type-specific tuning of hippocampal interneuron firing during gamma oscillations in vivo. J Neurosci 27: 8184-8189.
73. Uhlhaas PJ, Haenschel C, Nikolic D, Singer W (2008). The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 34: 927-943.
74. Uhlhaas PJ, Singer W (2010). Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11: 100-113.
75. Uhlhaas PJ, Singer W (2013). High-frequency oscillations and the neurobiology of schizophrenia. Dialogues Clin Neurosci 15: 301-313.
76. Van Drongelen W (2006). Signal Processing for Neuroscientists: An Introduction to the Analysis of Physiological Signals. Academic Press: Burlington, MA, USA.
77. Vardakou I, Pistos C, Spiliopoulou C (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197: 157-162.
78. Wang XJ (2010). Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev 90: 1195-1268.
79. Wilkinson ST, D'Souza D (2014). Problems with the medicalization of marijuana. JAMA 311: 2377-2378.
80. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296: 678-682.
81. Zeger SL, Liang K-Y (1986). Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121-130.